Peginterferon antiviral treatment after liver cancer surgery
Part of Cancer, Digestive system clinical trials.
This trial studies an antiviral medicine given after surgery for liver cancer to help prevent the cancer from coming back. It focuses on people who are hepatitis B–positive (HBsAg positive) and have complete remission on follow-up checks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 65 years old
- Have liver cancer removed with radical surgery or radiofrequency ablation, with complete remission confirmed within 4 weeks
- Have hepatitis B (HBsAg positive)
- Doctor says you can take peginterferon and a nucleoside/nucleotide antiviral medicine
- Agree to sign informed consent and follow study visit/medication rules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests whether a drug called pegylated interferon alpha-2β can help prevent hepatitis B-related liver cancer from coming back after surgery. The drug aims to boost your immune system to fight any remaining cancer cells.
This study tests an added hepatitis B immune medicine (HBV immunoglobulin) in people with chronic hepatitis B who have liver cancer and are planning surgery or a liver transplant. The goal is to see if giving this protection around the time of treatment can help prevent liver cancer from coming back or worsening.
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
This trial tests whether the immunotherapy drug Sintilimab, given after surgery, can help prevent liver cancer from coming back in people whose tumors had tiny blood vessel invasion. It is for patients who have fully recovered from surgery and have not had other cancer treatments before.
This trial tests whether continuing antiviral therapy after surgery for hepatitis B-related liver cancer can improve outcomes. It focuses on patients with early-stage disease, good liver function, and no prior cancer treatments other than surgery or ablation.
This study tests a drug called peginterferon alfa-2b for people with advanced liver cancer that cannot be removed by surgery and who also have hepatitis B. The drug aims to boost the immune system to fight the cancer and may help control the disease.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.